Simon Lord - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Simon Lord's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Simon Lord
Verified
Owner, Franchise New Zealand
Auckl
Beats
banking, college planning children's finance, real estateInvesting, taxes economics, and more. interest rates
Content
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib | Nature Communications
By R. C. Coombes, Simon Lord, Zahi Mitri, Carlo Palmieri, William Gradishar, Patrick Ward, Rinath Jeselsohn, Simak Ali| Nature Verified Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer - British Journal of Cancer
By Simon Lord| Nature Verified AbstractBreast cancer is the most common cancer in women, and incidence rates are rising, it is thought in part, due to increasing levels of obesity. Endocrine therapy (ET) remains the cornerstone of systemic therapy for early and advanced oestrogen receptor-positive (ER + ) breast cancer, but despite treatment advances, it is becoming more evident that obesity and insulin resistance are associated with worse outcomes.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib | Nature Communications
By R. C. Coombes, Simon Lord, Zahi Mitri, Carlo Palmieri, William Gradishar, Patrick Ward, Rinath Jeselsohn, Simak Ali| Nature Verified Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...
Company Info
Franchise New Zealand
Auckland, Auckland, New Zealand
+64 9-274 2901